nemo binimetinib shows promising activity nras-mutant cutaneous melanomaNemo在突变皮肤黑色素瘤中表现出有希望活性.pptx

下载文档

0
0
约6.26千字
约 10页
2025-02-24 发布于北京
举报
版权申诉
保障服务

nemo binimetinib shows promising activity nras-mutant cutaneous melanomaNemo在突变皮肤黑色素瘤中表现出有希望活性.pptx

1、本文档共10页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

CCOIndependentConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-June7,2016NEMO:BinimetinibShowsPromisingActivityinNRAS-MutantCutaneousMelanoma*CCOisanindependentmedicaleducationcompanythatprovidesstate-of-the-artmedicalinformationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,Incyte,Merck,andTaihoPharmaceuticals.

NEMO:BinimetinibinNRAS-MutantMelanomaNRAS-mutantmelanomaismoreaggressivewithlessfavorableprognosis[1]~20%ofmetastaticmelanomaptshaveNRASmutations[2]SubstantialunmetclinicalneedforNRASmelanomatherapies,particularlyafterfailureofimmunotherapyBinimetinib:selective,oral,petitiveMEK1/2inhibitor[3]NRAS-mutantmelanomashowntobesensitivetoMEKinhibitioninpreclinicalstudies[4]PhaseIIstudydemonstratedclinicalactivityofbinimetinibinadvancedNRAS-mutantmelanoma,[5]withaconfirmedORRof14.5%[6]CurrentrandomizedphaseIIItrialevaluatedefficacy,safetyofbinimetinibinptswithNRAS-mutantmelanoma[7]1.JakobJA,etal.Cancer.2012;118:4014-4023.2.LeeJH,etal.BrJDermatol.2011;164:776-784.

3.LeePA,etal.CancerRes.2010;70(8suppl).Abstract2515.4.SolitDB,etal.Nature.2006;439:358-362.

5.AsciertoPA,etal.LancetOncol.2013;14:249-256.6.vanHerpenC,etal.ESMO2014.AbstractLBA35.

7.DummerR,etal.ASCO2016.Abstract9500.Slidecredit:

NEMO:StudyDesignPrimaryendpoint:PFS(perblindedICR)Secondaryendpoints:OS,ORR,DCRSlidecredit:DummerR,etal.ASCO2016.Abstract9500.PtswithunresectableormetastaticcutaneousorunknownprimaryNRAS-mutantmelanoma;untreatedorPDon/afterimmunotherapy;ECOGPS0-1;NRASQ61mutation;stablebrainmetsallowed(N=402)*n=19ptsnottreated.?Priorimmunotherapyforunresectable/metastaticdisease.Stratifie